A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Multiple Oral Dosing in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2013
Price : $35 *
At a glance
- Drugs LY 3045697 (Primary) ; Spironolactone
- Indications Heart failure; Hypertension
- Focus Adverse reactions
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned End Date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 23 May 2013 Planned initiation date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.